Proposal in Congress

Combating Illicit Xylazine Act

Record date · Sep 16, 2026

What this means

Status
Proposal in Congress
What happened
Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq , is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III con…
What to check next
See the latest action below for the next step in Congress.
Check the original record

About this record

Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq , is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused. Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA. The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs. The bill also exempts xylazine manufacturers from the CSA's physical security requirements. Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.

Record details

Bill number
H.R. 1266
Congress
119
Introduced
2025-02-12
Sponsor
Rep. Panetta, Jimmy [D-CA-19]
Committees
Judiciary Committee; Energy and Commerce Committee
Latest documented action
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.

Documented actions

  1. Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.

  2. Motion to reconsider laid on the table Agreed to without objection.

  3. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)

  4. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

  5. DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.

  6. Considered under suspension of the rules. (consideration: CR H5671-5673)

  7. Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

  8. Placed on the Union Calendar, Calendar No. 715.

Sources and related records

Source checked .